SantoSolve has presented additional 2PX clinical data at the Annual European Congress of Rheumatology, the annual conference of the European League Against Rheumatism
(EULAR), which took place from June 16 to June 19 in Rome, Italy.

SantoSolve has recently completed patient enrollment in the first pivotal phase III trial for 2PX in patients with osteoarthritis of the knee (OA-03 study) with patients having been randomized across 21 centers in Northern Europe and Russia.

Norwegian pharmaceutical/biotech company SantoSolve AS has raised USD 5.5 million in a private placement with Scandinavian VCs Teknoinvest, InnovationsKapital and Investinor.

Chronic residual limb pain following amputation is a major problem for many patients, yet no effective pharmaceutical treatment is currently available.

SantoSolve has been informed that the company has been granted a Chinese patent for the use of non-radioactive strontium to treat sub-dermal pain conditions.

SantoSolve AS has successfully raised another round of financing, to be used to fund a planned Phase III trial in osteoarthritis of the knee for the company's topical pain product 2PX.

SantoSolve, a biopharmaceutical company focused on developing novel pain therapies today announced positive results from its Phase II study of 2PX, the company's topical analgesic, in patients with osteoarthritis (OA).

SantoSolve AS has completed a new financing round raising USD 7 million. The investments have been made by the Norwegian investors DnBNor, Gezina and Glastad Invest, together with the existing investors - Teknoinvest and InnovationsKapital.